CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We meet patients’ needs using the latest technologies to develop and deliver innovative therapies. The company offers a broad range of products in the industry for treating coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and chronic inflammatory demyelinating polyneuropathy (CIDP). CSL Behring’s products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn.